

# Fax



## DIVISION OF ONCOLOGY DRUG PRODUCTS

Center for Drug Evaluation and Research, HFD-150  
Parklawn Building  
5600 Fishers Lane, Rockville, MD 20857

<b>To:</b> John Worzalla/ LILLY	<b>From:</b> Alvis Dunson, Project Manager
<b>Fax:</b> 317 276-1652	<b>Fax:</b> 301-594-0498
<b>Phone:</b> 317 276-5052	<b>Phone:</b> 301-594-5767
<b>Pages:</b> 1	<b>Date:</b> January 6, 2000
<b>Re:</b> IND 40,061/serial nos. 200 and 201	

- Urgent   
  For Review   
  Please Comment   
  Please Reply   
  Please Recycle

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination or other action based on the content of the communication is not authorized. If you have received this document in error, please immediately notify us by telephone and return it to us at the above address by mail. Thank you.

● **Comments:**

Please refer to your submissions (2) dated December 22, 1999, for LY231514 (MTA).

We have reviewed these submissions and have the following comment.

The medical officer does not support adding vitamins to the ongoing mesothelioma registration trial. The medical officer has reviewed the letter (serial #201) and the Protocol Amendment H3E-MC-JMCH(c) (serial #200) and does not support the proposed plan to add vitamins to this pivotal trial.

If you have any questions please call me at (301) 594-5767.

Thank you,

Alvis Dunson

